SCHEMBL14367442

SCHEMBL14367442

Cc1c(CN(C)C(=O)c2cc3nc(-c4cccs4)cc(C(F)(F)F)n3n2)cnn1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 14/20 0.62
ALDH1A1 P00352 12/20 0.62
APOBEC3A P31941 1/20 0.62
HTT P42858 1/20 0.62
GAA P10253 5/20 0.59
MAPT P10636 3/20 0.59
HSD17B10 Q99714 4/20 0.56
CASP1 P29466 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
TSHR P16473 1/20 0.56
KMT2A Q03164 3/20 0.54
CASP7 P55210 2/20 0.54
MEN1 O00255 2/20 0.54
PKM P14618 1/20 0.54
MYC P01106 1/20 0.52
MAX P61244 1/20 0.52
L3MBTL1 Q9Y468 4/20 0.52
RXFP1 Q9HBX9 1/20 0.52
HPGD P15428 7/20 0.51
NPSR1 Q6W5P4 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4200448 0.88 ALDH1A1 (0.73) KDM4EALDH1A1APOBEC3AHTTGAA
SCHEMBL14367451 0.83 ALDH1A1 (0.56) KDM4EALDH1A1HTTMAPTHSD17B10
SCHEMBL3277995 0.78 KDM4E (1.00) KDM4EALDH1A1APOBEC3AHTTGAA
SCHEMBL1717948 0.77 KDM4E (0.71) KDM4EALDH1A1APOBEC3AHTTGAA
SCHEMBL1719321 0.76 HPGD (0.69) KDM4EALDH1A1APOBEC3AHTTGAA
SCHEMBL14014121 0.76 KDM4E (0.78) KDM4EALDH1A1APOBEC3AHTTGAA
SCHEMBL30382020 0.75 KDM4E (0.82) KDM4EALDH1A1APOBEC3AHTTGAA
SCHEMBL1718871 0.75 ALDH1A1 (0.54) KDM4EALDH1A1MAPTHSD17B10CASP1
SCHEMBL4197490 0.73 KDM4E (0.74) KDM4EALDH1A1APOBEC3AHTTGAA
SCHEMBL1718395 0.73 KDM4E (0.78) KDM4EALDH1A1APOBEC3AHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070270408-A1 Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines NOVO NORDISK A/S (DK) 2007-11-22 US disclosed
US-20070270408-A1 Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines NOVO NORDISK A/S (DK) 2007-11-22 US disclosed
EP-1782859-A2 Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines NOVO NORDISK A/S (DK) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270408-A1 Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines HSD3B1, HSD11B1, SRD5A1 KDM4E 3872/4885ALDH1A1 133/4885APOBEC3A 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.